SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer Jim Hitchin. The interview, in its entirety, is available on the company's website at http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/Wall%20Street%20Transcript.pdf
Mr. Hitchin said, "Each year there are literally hundreds of thousands of cases of colorectal, cervical and esophageal cancer which, because they are not diagnosed or caught early enough, result in higher mortality rates and higher costs. Our technology enables physicians to more accurately diagnose these diseases, and to do so at an earlier stage. This is critical to reducing deaths from cancer and to reducing overall costs to the healthcare system."
SpectraScience's technology provides the healthcare community with the promise of a higher degree of objectivity and sensitivity in the cancer screening process for colon cancer and cervical cancer. It is also undergoing clinical trials for an esophageal cancer screening application.
During the interview, Mr. Hitchin also reiterated that the company is focusing all resources in sales, adding that it has a competitive advantage from a technology standpoint and that there are no direct competitors to its cancer screening platforms. He emphasized that the chance to detect cancers early, or much earlier than is currently the case, means more people are going to live longer.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 19
|SOURCE SpectraScience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved